<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04952909</url>
  </required_header>
  <id_info>
    <org_study_id>S01-CLN-002</org_study_id>
    <nct_id>NCT04952909</nct_id>
  </id_info>
  <brief_title>The ShortCut™ Study Protocol</brief_title>
  <official_title>A Prospective, Multicenter, Non-Randomized, Single-Arm, Open-Label Clinical Study to Demonstrate the Safety and Effectiveness of the ShortCut™ Device (The ShortCut™ Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pi-cardia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pi-cardia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Prospective, Multicenter, Non-Randomized, Single-Arm, Open-Label Clinical Study to&#xD;
      Demonstrate the Safety and Effectiveness of the ShortCut™ for splitting bioprosthetic aortic&#xD;
      valve leaflets in patients who are presented for a valve-in-valve transcatheter aortic valve&#xD;
      replacement (TAVR) procedure, and who are at risk for TAVR-induced coronary artery&#xD;
      obstruction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ShortCut™ device and/or ShortCut™ procedure-related serious adverse events</measure>
    <time_frame>Intra-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Successful leaflet splitting</measure>
    <time_frame>Intra-procedure</time_frame>
    <description>Assessed by echo and/or aortography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of all-cause mortality</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>(VARC-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of all-cause stroke</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>(VARC-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of myocardial infarction with new evidence of coronary artery obstruction requiring intervention</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>(VARC-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of major vascular complications</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>(VARC-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of access-related type 3-4 bleeding</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>(VARC-3)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of all-cause mortality</measure>
    <time_frame>90 days post procedure</time_frame>
    <description>(VARC-3)</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>90 days post procedure</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Risk of Coronary Obstruction Following TAVR Procedure</condition>
  <arm_group>
    <arm_group_label>ShortCut™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ShortCut™</intervention_name>
    <description>Splitting bioprosthetic aortic valve leaflets</description>
    <arm_group_label>ShortCut™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient requires a percutaneous valve-in-valve procedure due to a failed bioprosthetic&#xD;
             valve and is at risk for TAVR-induced coronary artery obstruction, based on the local&#xD;
             Heart Team decision.&#xD;
&#xD;
          -  Written informed consent to participate in the study obtained from the subject or&#xD;
             subject's legal representative, according to local regulations, prior to initiation of&#xD;
             any study mandated procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  An excessive aortic valve leaflet Calcium morphology or anatomy not suitable for the&#xD;
             use of the ShortCut™ device.&#xD;
&#xD;
          -  Coronary, carotid or vertebral disease that, in the opinion of the local Heart Team,&#xD;
             should be treated; or treatment of such disease ≤ 1 month prior to index procedure.&#xD;
&#xD;
          -  CVA or TIA ≤ 6 months prior to index procedure, or severe neurological disability.&#xD;
&#xD;
          -  Myocardial infarction (MI) ≤ 6 weeks prior to index procedure.&#xD;
&#xD;
          -  Hemodynamic or respiratory instability.&#xD;
&#xD;
          -  Left ventricle ejection fraction &lt; 30%.&#xD;
&#xD;
          -  Ongoing severe infection, sepsis or endocarditis.&#xD;
&#xD;
          -  Renal insufficiency, unless on dialysis.&#xD;
&#xD;
          -  Need for emergency surgery for any reason.&#xD;
&#xD;
          -  Life expectancy is less than 90 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Merav Gat</last_name>
    <phone>+97289484800</phone>
    <email>merav@pi-cardia.net</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>June 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

